FY2027 Q1
27 Jul 2026
-
Hi. I hope I am audible.
Read in transcript -
Yes. Congratulations, sir, on great set of numbers. Sir, my first question is when we look at emerging market EBITDA margins over the last year, we have seen improvement sequentially and yearly. But now when we look at Q1 FY27, it has gone down from 20% in Q4 FY26 to 14% in Q1 FY27. So, what would be the reason for this?
Read in transcript -
Got it. Sir, second question is on the branded generics and this time we have not seen a growth in that segment. In fact, there is a de-growth of 2%. So, do you think we'll come back in that segment as well?
Read in transcript